Unlike traditional brain stimulation methods that often target superficial cortical areas, tTIS leverages high-frequency electrical interference patterns to modulate activity deep within the brain with unprecedented precision. This cutting-edge technology can selectively influence structures implicated in schizophrenia’s pathophysiology, such as the nucleus accumbens (NAc), a key player in reward processing and motivation. The study specifically targets the right NAc to assess whether modulating this deep brain region can alleviate cognitive impairments and the pervasive negative symptoms seen in schizophrenia patients.

The significance of this approach lies in its ability to circumvent several limitations of past neuromodulation techniques. Conventional transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) typically affect more superficial brain regions and often lack the spatial resolution required to engage critical subcortical nuclei. By contrast, tTIS employs two high-frequency electrical currents with slightly different frequencies, which intersect to produce an interference pattern at a targeted depth, thereby stimulating neuronal populations without affecting overlying cortex. This refined control potentially allows for more effective and side-effect-free therapeutic interventions.

This landmark study plans to recruit 76 individuals diagnosed with schizophrenia who exhibit pronounced cognitive deficits and negative symptoms. These participants will be randomly assigned to receive either active tTIS or a sham (placebo) stimulation, ensuring rigorous double-blind conditions. Importantly, all subjects will maintain stable antipsychotic medication regimens throughout the study to isolate the effects of the brain stimulation intervention from pharmacotherapy changes.

The intervention consists of ten weekday sessions, each lasting 30 minutes, designed to deliver tailored stimulation based on each participant’s neuroanatomy. Advances in neuroimaging and computational modeling enable customized electrode placement to optimize current distribution and focality. This individualized approach is critical given the variability in brain anatomy and the complex network dysfunctions underlying schizophrenia.

Outcomes will be evaluated at four time points—baseline (prior to treatment), immediately post-intervention, and at two and four weeks following the final session. The primary endpoint centers on cognitive improvement, assessed using the MATRICS Consensus Cognitive Battery (MCCB), a comprehensive and widely-validated neuropsychological test battery specifically designed for schizophrenia research. Given cognition’s central role in determining functional outcomes, any positive findings could dramatically alter treatment approaches.

Secondary measures will probe a broad array of symptom domains, including positive and negative symptoms, mood disturbances such as depression and anxiety, sleep quality, and overall quality of life. The study also incorporates resting-state functional magnetic resonance imaging (rs-fMRI) to elucidate the neural mechanisms underpinning clinical changes, potentially correlating alterations in network connectivity or activity with symptomatic improvements.

If successful, this trial would constitute the first rigorous randomized controlled evidence supporting tTIS as a viable therapy to target cognitive deficits and negative symptoms in schizophrenia. Such evidence is desperately needed since these symptom clusters are notoriously resistant to existing pharmacological treatments, which primarily address positive symptoms like hallucinations and delusions.

Moreover, the implications extend beyond schizophrenia. The ability to modulate deep brain regions non-invasively with high specificity opens new horizons for treating other neuropsychiatric and neurological disorders characterized by dysfunctional subcortical circuits. Disorders ranging from depression and obsessive-compulsive disorder to Parkinson’s disease could potentially benefit from adaptations of tTIS protocols.

The upcoming trial also reflects a broader shift in psychiatric research, increasingly prioritizing individualized, circuit-based interventions informed by neurobiological insights rather than symptom-driven, one-size-fits-all treatments. This precision approach aims to enhance therapeutic efficacy while minimizing side effects, an especially urgent goal for patients with severe mental illness.

This initiative received ethical approval and plans to commence patient recruitment in late May 2025 at sites registered with the Chinese Clinical Trial Registry (ChiCTR2500102724). Researchers express optimism that the study’s findings will illuminate not only the clinical benefits but also the neural dynamics of tTIS, contributing critical data to the rapidly evolving field of neuromodulation.

In summary, individualized transcranial temporal interference stimulation represents a frontier technology with the potential to transform the landscape of schizophrenia treatment. By precisely targeting deep brain structures implicated in cognition and motivation, this method seeks to fill an unmet clinical need: the effective and safe amelioration of cognitive and negative symptoms that have long defied intervention.

As neuroscience and engineering converge to develop such innovative tools, the hope is that patients previously left behind by traditional therapies will gain new avenues toward recovery, improved function, and ultimately, a better quality of life.

Subject of Research: Individualized transcranial temporal interference stimulation (tTIS) targeting cognitive impairments and negative symptoms in schizophrenia.

Article Title: Individualized transcranial temporal interference stimulation (tTIS) for cognitive impairments and negative symptoms in patients with schizophrenia: a study protocol for a randomized controlled trial.

Article References:
Wang, S., Chen, J., Wang, L. et al. Individualized transcranial temporal interference stimulation (tTIS) for cognitive impairments and negative symptoms in patients with schizophrenia: a study protocol for a randomized controlled trial. BMC Psychiatry 25, 714 (2025). https://doi.org/10.1186/s12888-025-07158-8

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07158-8

The subthalamic nucleus forms part of the basal ganglia circuitry, playing a critical role in movement regulation. Parkinson’s disease, characterized by dopaminergic neuron degeneration, disrupts these basal ganglia pathways, leading to the hallmark motor impairments such as bradykinesia, rigidity, and tremor. Deep brain stimulation (DBS) targeting the STN has become a cornerstone in managing advanced PD, primarily operated via implanted electrodes that deliver electrical impulses to modulate dysfunctional neural activity. However, fine-tuning DBS parameters and maximizing treatment efficacy over years remain challenging due to variable biomarker reliability and underlying neural plasticity.

The study uniquely addresses this clinical gap by examining the stability of two distinct physiomarkers derived from LFP recordings: periodic oscillatory activities, such as beta-band rhythms, and aperiodic components, which reflect broadband spectral features potentially linked to neural excitation-inhibition balance. Traditionally, periodic beta oscillations (~13-30 Hz) have been extensively studied, with elevated beta power correlating negatively with motor performance and responsiveness to dopaminergic therapies. Yet, aperiodic neural dynamics, representing scale-free fluctuations in the frequency domain, have emerged as complementary indicators of underlying neural state and are gaining traction in neurophysiological research.

Employing an advanced longitudinal design, Stam et al. implanted directional DBS leads capable of chronic LFP monitoring in a cohort of PD patients. This approach permitted recording subthalamic signals over an extended timeframe of months to years, circumventing the limitations inherent in short-term laboratory assessments. By systematically analyzing the spectral features from these datasets, the researchers quantified the intra-individual variability of periodic beta oscillations and aperiodic broadband components, thereby assessing their temporal robustness.

A critical revelation from the analysis was the remarkable long-term consistency of both physiomarkers. Beta-band oscillations demonstrated stable oscillatory peaks in frequency and power, maintaining their spatial focality within the STN despite ongoing disease progression and therapeutic adjustments. Concurrently, the aperiodic exponent, which characterizes the slope of the power spectral density, showed minimal drift over time, suggesting that the neural excitation-inhibition balance indexed by this feature is a steadfast characteristic of subthalamic physiology in PD patients.

This constancy has profound implications for the design of adaptive DBS systems, also known as closed-loop neuromodulation. These systems rely on feedback from reliable biomarkers to dynamically adjust stimulation parameters in response to the patient’s neural state, aiming to enhance clinical outcomes and reduce side effects. The demonstration that both periodic and aperiodic features endure longitudinally argues strongly for their incorporation into real-time DBS control algorithms. Unlike biomarkers susceptible to transient fluctuations, these physiomarkers could serve as stable anchors facilitating personalized neuromodulation that adapts intelligently over the course of treatment.

Moreover, the distinction between periodic and aperiodic components opens novel vistas in understanding PD pathophysiology. While pathological beta synchrony has long been associated with motor impairment, the aperiodic spectral features may relate more fundamentally to network excitation levels and synaptic homeostasis within the STN and its broader basal ganglia context. The preserved aperiodic exponent suggests a maintained cortical-subcortical balance or a stable underlying neural noise floor, both of which could influence how the basal ganglia circuits process motor commands and respond to dopaminergic modulation.

This study also highlights the technical advancements enabling such comprehensive long-term monitoring. The use of directional DBS electrodes enhances spatial resolution, allowing precise localization of physiomarker sources and minimizing contamination from adjacent neural structures. Coupled with sophisticated signal processing pipelines capable of disentangling oscillatory and non-oscillatory signal components, these innovations are ushering in an era where nuanced understanding of brain oscillations can be integrated into everyday clinical practice.

Despite these advances, the authors also caution about inherent complexities in interpreting LFP data. Factors such as individual anatomical variability, electrode positioning, medication status, and disease heterogeneity contribute to subtle variations in the recorded signals. Therefore, while physiomarkers show resilience, developing robust algorithms capable of accommodating these inter- and intra-individual differences remains an ongoing challenge. Nonetheless, this comprehensive dataset provides an invaluable foundation for translational research aimed at refining biomarker-guided DBS paradigms.

Importantly, the findings underscore the necessity of incorporating both periodic and aperiodic signal characteristics when defining physiomarkers in PD. Prior DBS optimization strategies have predominantly fixated on beta oscillations as the primary feedback signal, which may only tell part of the story. By integrating aperiodic signal metrics, future approaches could harness complementary neurophysiological information reflective of broader circuit dynamics, potentially enhancing therapeutic precision and patient-specific customization.

Furthermore, these insights carry broader implications beyond Parkinson’s disease. The methodology and analytical framework developed in this research can be adapted to other neurological disorders where abnormal neural oscillations and altered excitation-inhibition balances play crucial roles, such as dystonia, essential tremor, and epilepsy. The notion of dissecting and tracking discrete spectral components over long periods sets a new standard for personalized neuromodulation therapies across diverse clinical contexts.

This study also invigorates discussions on the biological basis of aperiodic neural activity, a topic garnering increasing attention in systems neuroscience. Aperiodic activity has been posited to reflect fundamental aspects of cortical microcircuit function, including synaptic input distributions and membrane potential fluctuations. The stability of the aperiodic exponent in PD patients’ STN offers empirical support for its role as a trait-like neural signature, opening avenues for further investigation into how disease processes perturb these fundamental electrical properties.

From a clinical viewpoint, the ability to track physiomarker stability longitudinally enhances patient monitoring and prognosis. Stable neural markers provide clinicians with reliable indicators to evaluate disease progression, therapeutic response, and potential adjustments in DBS programming. Moreover, continuous LFP monitoring embedded within implanted devices could facilitate remote, real-time assessment of PD motor states, reducing the need for frequent clinical visits and fostering proactive disease management.

As the field moves towards precision neuromodulation, the contribution of Stam and colleagues represents a significant paradigm shift. By meticulously validating the long-term consistency of physiomarkers in the subthalamic nucleus, this work lays the groundwork for next-generation closed-loop DBS systems that are both adaptive and durable. Future studies expanding these findings to larger, more diverse patient populations will be critical in generalizing these principles and integrating them into routine clinical workflows.

In sum, this landmark investigation redefines our understanding of Parkinsonian neurophysiology, highlighting that both oscillatory beta rhythms and aperiodic spectral features are not transient artifacts but rather stable signatures embedded within the subthalamic circuitry. These findings empower researchers and clinicians alike to envision a future where tailored neuromodulation strategies leverage reliable electrophysiological physiomarkers, ultimately improving quality of life for millions affected by Parkinson’s disease worldwide.

Subject of Research:
Long-term stability of periodic and aperiodic physiomarkers in subthalamic local field potentials in Parkinson’s disease

Article Title:
Long-term consistency of aperiodic and periodic physiomarkers in subthalamic local field potentials in Parkinson’s disease

Article References:

Stam, M.J., van Wijk, B.C.M., Buijink, A.W.G. et al. Long-term consistency of aperiodic and periodic physiomarkers in subthalamic local field potentials in Parkinson’s disease. npj Parkinsons Dis. 11, 204 (2025). https://doi.org/10.1038/s41531-025-01053-5

Image Credits: AI Generated

DBS involves the surgical implantation of electrodes into specific areas of the brain, typically the subthalamic nucleus (STN) or globus pallidus internus (GPi), which deliver electrical pulses to modulate neural activity. While clinical benefits of DBS for tremor and rigidity have been well established, its effects on gait have been inconsistent. This variability stems in part from the complex neural circuits governing locomotion and the heterogeneous pathological processes within PD. To address these challenges, Fekri Azgomi and colleagues have pioneered computational models that decode the intricate neuronal dynamics underlying gait disturbances and simulate the impact of targeted stimulation.

The core innovation of their study lies in integrating patient-specific neurophysiological data—obtained through electrophysiological recordings and neuroimaging—with advanced computational algorithms. By applying biophysical models of neuronal populations, the researchers were able to replicate abnormal oscillatory patterns associated with gait dysfunction. These models then served as a virtual testbed to explore how different DBS parameter configurations influence network activity. Such in silico trials offer the advantage of rapid hypothesis testing without the risks and costs inherent to clinical experimentation.

One fundamental insight from their models relates to the phase and frequency of stimulation signals. Traditional DBS protocols typically adopt constant-frequency pulses, but the team’s simulations demonstrated that dynamically modulated stimulation, synchronized to the limb movement cycle, could restore more physiological oscillatory patterns. This time-locked approach appears to recalibrate defective neural circuitry involved in the initiation and execution of gait, enhancing the rhythmicity and stability of walking movements. The concept of closed-loop DBS, responding adaptively to ongoing neural feedback, aligns closely with these findings.

Moreover, the researchers uncovered that the spatial targeting of electrodes is crucial in maximizing gait improvement. Through detailed anatomical reconstructions and diffusion tensor imaging tractography, the models identified specific white matter pathways and subregions within the basal ganglia-thalamocortical circuitry that are key nodes in locomotor control. Tailoring stimulation to preferentially engage these pathways enhanced therapeutic benefits while minimizing side effects such as dyskinesias or speech disturbances, which often limit DBS tolerability.

Another notable achievement of this work is the incorporation of variability observed among individual patients into the models. Parkinson’s disease exhibits significant clinical heterogeneity, with gait impairments manifesting differently across patients depending on disease stage, genetic background, and comorbidities. By parameterizing the models with personalized electrophysiology and imaging data, the researchers created individualized virtual brains. This personalized modeling approach enables prediction of optimal stimulation settings for each patient, reducing the reliance on trial-and-error programming that currently prolongs DBS optimization in clinical practice.

Furthermore, this modeling framework sheds light on underlying disease mechanisms, offering a window into how pathological beta-band oscillations disrupt locomotor circuits. The excessive synchronization in the beta frequency range within STN and connected regions has long been implicated in motor deficits of PD. Through simulation, the authors demonstrated how carefully timed DBS pulses could desynchronize these pathological rhythms, thereby unmasking residual motor functionality. This mechanistic understanding bridges a critical gap between basic neuroscience and clinical intervention.

The implications of this research extend beyond gait improvement alone. The modeling strategy presents a versatile tool to investigate other complex PD symptoms such as freezing of gait—a transient inability to initiate steps—and postural instability. These phenomena are notoriously difficult to manage pharmacologically and often respond poorly to conventional stimulation. By simulating diverse neural conditions and stimulation paradigms, the platform serves as a powerful resource for designing novel DBS modalities to target these intractable symptoms.

Importantly, the study emphasizes the integration of multi-modal data streams encompassing electrophysiological signals, structural connectivity, and behavioral assessments. This holistic approach aligns with the emerging precision medicine paradigm, where therapy is customized based on detailed phenotypic and biological information. The researchers advocate for the deployment of their modeling tools alongside wearable sensors and real-time neural monitors to enable continuous adaptive DBS in ambulatory settings, thus overcoming limitations of static programming during clinic visits.

Despite these promising advances, challenges remain before routine clinical adoption can be realized. The computational complexity of the models demands significant processing power and sophisticated software interfaces accessible to clinicians. Ethical considerations also arise around the safe implementation of adaptive neurostimulation systems that autonomously alter brain activity. To address these issues, interdisciplinary collaborations bridging neuroscience, engineering, and clinical neurology will be essential in translating these findings into practical therapies.

Nonetheless, the potential benefits are profound. Personalized DBS optimized through computational modeling could revolutionize the therapeutic landscape for millions suffering from PD worldwide. Improvements in gait and mobility translate directly into enhanced independence and reduced caregiver burden, while minimizing stimulation-induced side effects improves overall quality of life. Such technology embodies the future of neuromodulation—intelligent, patient-specific, and deeply informed by neural science.

Beyond Parkinson’s disease, the modeling framework may find application in other movement disorders treated with DBS, such as dystonia and essential tremor. Moreover, lessons learned from dissecting gait circuits could inform neurorehabilitation strategies post-stroke or spinal cord injury. The convergence of computational neuroscience and clinical neurology exemplified in this work epitomizes a new era in brain health, where virtual trials expedite the discovery and deployment of safe, effective brain therapies.

In summary, the pioneering research by Fekri Azgomi, Louie, Bath, and colleagues presents a compelling vision for the future of DBS in Parkinson’s disease. By leveraging personalized neurophysiological data and sophisticated modeling techniques, they have charted a course toward optimizing stimulation protocols that directly target debilitating gait impairments. Their work not only advances fundamental understanding of basal ganglia circuitry but also sets the stage for transformative clinical innovations that promise to restore ambulatory function and improve lives on an unprecedented scale.

As the field progresses, future studies may expand the computational toolkit to incorporate additional biological complexities such as neurochemical dynamics, immune responses, and long-term plasticity effects induced by chronic stimulation. Integration with adaptive machine learning algorithms could further refine stimulation algorithms in real time. Combined clinical trials validating these approaches will be critical to definitively prove safety and efficacy, paving the way for regulatory approvals and broad dissemination.

What remains clear is the immense promise harnessed at the intersection of neuroengineering and precision medicine. The quest to restore gait in Parkinson’s disease illustrates how bridging fundamental neuroscience with cutting-edge technology can unravel the complexity of brain disorders. Personalized DBS, informed by detailed computational models, may soon transform what was once a standard palliation into a dynamic, fine-tuned intervention that empowers patients to walk steadily again, reclaiming mobility and hope.

Subject of Research: Parkinson’s disease gait dysfunction and optimization of deep brain stimulation through personalized neurophysiological modeling.

Article Title: Modeling and optimizing deep brain stimulation to enhance gait in Parkinson’s disease: personalized treatment with neurophysiological insights.

Article References:
Fekri Azgomi, H., Louie, K.H., Bath, J.E. et al. Modeling and optimizing deep brain stimulation to enhance gait in Parkinson’s disease: personalized treatment with neurophysiological insights. npj Parkinsons Dis. 11, 173 (2025). https://doi.org/10.1038/s41531-025-00990-5

Image Credits: AI Generated